Endothelial Injury Following CAR-T Cell Immunotherapy for Hematological Malignancies
Cancers · 01.09.2025 · 17 (17) · 2876
DOI: 10.3390/cancers17172876 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 01.09.2025. Verfasst von Christos Demosthenous und 8 weiteren Autor:innen. Beteiligte Einrichtung: BMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor-T (CAR-T) cell immunotherapy constitutes a cornerstone in the management of patients with relapsed/refractory B-cell lineage lymphoid malignancies. Toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematotoxicity (ICAHT) have been recognized in the post-infusion period. The initial interplay between CAR-T cells and tumor cells, followed by cytokine release and the bystander activation of the innate immunity cells, result in endothelial cell injury. In the current review, the ongoing research regarding endothelial injury in CAR-T cell recipients is summarized. Various markers of endothelial injury have been investigated in CAR-T cell recipients, including markers of complement activation, such as soluble C5b-9, endothelial dysfunction (angiopoietin-2, VCAM1, ICAM-1), inflammation, and thrombosis (von Willebrand antigen, ADAMTS13, thrombomodulin). The expression level of these endothelial injury markers has been identified as impaired in CAR-T cell recipients, not only when compared with healthy controls but also among patients with severe CRS/ICANS and those with mild toxicities or without toxicities. Furthermore, the Endothelial Activation and Stress Index (EASIX) and modified versions of this score, calculated in the pre- and early post-infusion period, seem to predict development of severe toxicities, ICAHT, and, thus, poor overall survival in CAR-T cell patients. More data concerning the role of these endothelial injury markers and clinical outcomes in CAR-T cell settings are essential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- BMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
- Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
- Translational Research and Laboratory Medicine Unit, First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
- Department of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
ORCID-Profile: Christos Demosthenous, Paschalis Evangelidis, Athanasios Gatsis, Ioannis Mitroulis, Eleni Gavriilaki
Zitieren
APA
Demosthenous, C., Evangelidis, P., Gatsis, A., Mitroulis, I., Vakalopoulou, S., Vardi, A., Bountoura, S., Sakellari, I., & Gavriilaki, E. (2025). Endothelial Injury Following CAR-T Cell Immunotherapy for Hematological Malignancies. Cancers, 17(17), 2876. https://doi.org/10.3390/cancers17172876
Vancouver
Demosthenous C, Evangelidis P, Gatsis A, Mitroulis I, Vakalopoulou S, Vardi A, et al. Endothelial Injury Following CAR-T Cell Immunotherapy for Hematological Malignancies. Cancers. 2025;17(17):2876. doi:10.3390/cancers17172876
BibTeX
@article{Demosthenous2025,
author = {Demosthenous, Christos and Evangelidis, Paschalis and Gatsis, Athanasios and Mitroulis, Ioannis and Vakalopoulou, Sofia and Vardi, Anna and Bountoura, Stefania and Sakellari, Ioanna and Gavriilaki, Eleni},
title = {Endothelial Injury Following CAR-T Cell Immunotherapy for Hematological Malignancies},
journal = {Cancers},
year = {2025},
volume = {17},
number = {17},
pages = {2876},
doi = {10.3390/cancers17172876}
}
EUVIMED